BioNTech SE (BNTX)
90.20
-0.68
(-0.75%)
USD |
NASDAQ |
May 08, 14:56
BioNTech Enterprise Value: 5.238B for May 7, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 07, 2024 | 5.238B |
| May 06, 2024 | 5.833B |
| May 03, 2024 | 5.682B |
| May 02, 2024 | 5.566B |
| May 01, 2024 | 5.014B |
| April 30, 2024 | 4.742B |
| April 29, 2024 | 4.532B |
| April 26, 2024 | 4.354B |
| April 25, 2024 | 4.233B |
| April 24, 2024 | 4.566B |
| April 23, 2024 | 4.662B |
| April 22, 2024 | 4.547B |
| April 19, 2024 | 4.257B |
| April 18, 2024 | 4.103B |
| April 17, 2024 | 4.159B |
| April 16, 2024 | 4.144B |
| April 15, 2024 | 4.518B |
| April 12, 2024 | 4.178B |
| April 11, 2024 | 4.306B |
| April 10, 2024 | 4.701B |
| April 09, 2024 | 5.038B |
| April 08, 2024 | 4.860B |
| April 05, 2024 | 4.856B |
| April 04, 2024 | 4.718B |
| April 03, 2024 | 4.918B |
| Date | Value |
|---|---|
| April 02, 2024 | 5.096B |
| April 01, 2024 | 5.474B |
| March 31, 2024 | 5.267B |
| March 28, 2024 | 3.879B |
| March 27, 2024 | 4.050B |
| March 26, 2024 | 3.748B |
| March 25, 2024 | 4.057B |
| March 22, 2024 | 3.779B |
| March 21, 2024 | 3.817B |
| March 20, 2024 | 3.344B |
| March 19, 2024 | 4.324B |
| March 18, 2024 | 4.055B |
| March 15, 2024 | 3.934B |
| March 14, 2024 | 4.036B |
| March 13, 2024 | 4.283B |
| March 12, 2024 | 4.706B |
| March 11, 2024 | 4.842B |
| March 08, 2024 | 3.646B |
| March 07, 2024 | 3.603B |
| March 06, 2024 | 3.675B |
| March 05, 2024 | 3.468B |
| March 04, 2024 | 3.178B |
| March 01, 2024 | 3.568B |
| February 29, 2024 | 3.097B |
| February 28, 2024 | 3.684B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
2.452B
Minimum
Oct 14 2019
107.68B
Maximum
Aug 09 2021
24.58B
Average
19.79B
Median
Aug 03 2020
Enterprise Value Benchmarks
| Pfizer Inc | 215.68B |
| Moderna Inc | 37.87B |
| Autolus Therapeutics PLC | 826.80M |
| Novavax Inc | 243.30M |
| BioVie Inc | 9.406M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -342.26M |
| Revenue (Quarterly) | 203.77M |
| Total Expenses (Quarterly) | 754.69M |
| EPS Diluted (Quarterly) | -1.423 |
| Gross Profit Margin (Quarterly) | 68.50% |
| Profit Margin (Quarterly) | -168.0% |
| Earnings Yield | 0.53% |
| Normalized Earnings Yield | 0.7646 |